Iat Reinsurance Co. LTD. Sells 50,000 Shares of Amgen, Inc. (NASDAQ:AMGN)
Iat Reinsurance Co. LTD. trimmed its stake in Amgen, Inc. (NASDAQ:AMGN) by 35.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 92,500 shares of the medical research company’s stock after selling 50,000 shares during the quarter. Amgen accounts for approximately 5.3% of Iat Reinsurance Co. LTD.’s holdings, making the stock its 4th biggest holding. Iat Reinsurance Co. LTD.’s holdings in Amgen were worth $18,753,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Salomon & Ludwin LLC raised its holdings in shares of Amgen by 125.0% during the fourth quarter. Salomon & Ludwin LLC now owns 108 shares of the medical research company’s stock valued at $26,000 after buying an additional 60 shares during the last quarter. Savior LLC acquired a new stake in Amgen in the 4th quarter valued at approximately $34,000. CLS Investments LLC raised its stake in Amgen by 175.4% during the 4th quarter. CLS Investments LLC now owns 157 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 100 shares in the last quarter. Sageworth Trust Co acquired a new position in Amgen during the 4th quarter worth $42,000. Finally, Altshuler Shaham Ltd boosted its position in Amgen by 273.9% during the 4th quarter. Altshuler Shaham Ltd now owns 172 shares of the medical research company’s stock worth $42,000 after acquiring an additional 126 shares during the period. 76.41% of the stock is owned by institutional investors.
In related news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total transaction of $100,856.75. Following the completion of the sale, the director now directly owns 5,834 shares in the company, valued at $1,384,466.54. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $229.27, for a total transaction of $229,270.00. Following the transaction, the director now directly owns 16,482 shares in the company, valued at $3,778,828.14. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,425 shares of company stock worth $563,477. Company insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.70 by $0.47. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. Amgen’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm posted $3.56 earnings per share. Equities analysts predict that Amgen, Inc. will post 15.58 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 8th. Shareholders of record on Monday, May 18th will be paid a dividend of $1.60 per share. The ex-dividend date is Friday, May 15th. This represents a $6.40 annualized dividend and a yield of 2.83%. Amgen’s dividend payout ratio (DPR) is presently 43.18%.
A number of equities research analysts recently weighed in on the stock. Bank of America lifted their price objective on shares of Amgen from $250.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, May 1st. SunTrust Banks boosted their price target on shares of Amgen from $254.00 to $265.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Cantor Fitzgerald increased their price objective on shares of Amgen from $255.00 to $263.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Oppenheimer started coverage on Amgen in a report on Friday, May 1st. They set a “buy” rating and a $252.00 target price on the stock. Finally, Barclays assumed coverage on Amgen in a research note on Thursday, February 27th. They set an “equal weight” rating and a $235.00 price target for the company. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seventeen have issued a buy rating to the company. Amgen has an average rating of “Buy” and an average price target of $244.65.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: How interest rates affect municipal bond prices
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.